0001656472-24-000027.txt : 20240305 0001656472-24-000027.hdr.sgml : 20240305 20240305172453 ACCESSION NUMBER: 0001656472-24-000027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GORENSTEIN MICHAEL RYAN CENTRAL INDEX KEY: 0001797199 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 24722452 MAIL ADDRESS: STREET 1: 111 PETER STREET, SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 4 1 wk-form4_1709677477.xml FORM 4 X0508 4 2024-03-01 0 0001656472 Cronos Group Inc. CRON 0001797199 GORENSTEIN MICHAEL RYAN 111 PETER STREET, SUITE 300 TORONTO A6 M5V 2H1 ONTARIO, CANADA 1 1 0 0 See remarks below 0 COMMON SHARES 2024-03-01 4 M 0 62659 0 A 9843797 D COMMON SHARES 2024-03-01 4 F 0 15620 2.08 D 9828177 D RESTRICTED STOCK UNITS 2024-03-01 4 M 0 62659 0 D COMMON SHARES 62659 4369574 D Each restricted stock unit ("RSU") represents a contingent right to receive one common share of Cronos Group Inc. Due to an inadvertent error, the Form 4 filed by the Reporting Person on December 15, 2023 incorrectly reported the amount of securities beneficially owned following reported transaction(s). This inadvertent error caused the amount of securities beneficially owned to be overstated by 973,618 shares. The new amount reported in Column 5 reports the correct amount of securities beneficially owned following reported transaction(s). On October 24, 2022, the reporting person was granted 125,318 RSUs, vesting in two substantially equal installments on each of March 1, 2023 and March 1, 2024. Due to an inadvertent error, the Form 4 filed by the Reporting Person on December 15, 2023 incorrectly reported the number of derivative securities beneficially owned following reported transaction(s). This inadvertent error caused the number of derivative securities beneficially owned to be understated by 1,947,235 shares. The new amount reported in Column 9 reports the correct number of derivative securities beneficially owned following reported transaction(s). Chairman, Chief Executive Officer, and President /s/ Aaron Werner, as attorney-in-fact for Michael R. Gorenstein 2024-03-05